MAFLD affects up to a third of the global population in parallel with a growing epidemic of obesity and T2DM.597 HFD can lead to a state of nonalcoholic fatty liver disease (NAFLD), accompanied by the decreased expression of PGC‐1α and subsequent hepatic inflammation. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatotic liver disease.